Clinical

Dataset Information

0

TAS-CC4 Study


ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2614211 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2645202 | ecrin-mdr-crc
| 2637697 | ecrin-mdr-crc
| 2637698 | ecrin-mdr-crc
| 2636928 | ecrin-mdr-crc
| 2635519 | ecrin-mdr-crc
| 2641267 | ecrin-mdr-crc
| 2646936 | ecrin-mdr-crc
| 2637963 | ecrin-mdr-crc
| 2628236 | ecrin-mdr-crc
2024-08-26 | GSE275628 | GEO